
Thursday, April 13, 2023 12:42:51 PM
We'll see if it's go time yet or not.

Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?
"We hope not." Richard Dennis
Liked By
Spread the love. Be the first to like this post!
Recent EVAX News
- Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea • GlobeNewswire Inc. • 09/20/2023 12:26:00 PM
- Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company • GlobeNewswire Inc. • 09/18/2023 12:23:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 09/13/2023 08:45:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/11/2023 12:17:07 PM
- Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development • GlobeNewswire Inc. • 09/11/2023 12:17:00 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 09/07/2023 08:45:04 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/31/2023 04:15:12 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/29/2023 01:22:42 PM
- Evaxion announces Executive Management Changes to strengthen the AI-strategy • GlobeNewswire Inc. • 08/29/2023 12:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 08/25/2023 09:00:53 PM
- Evaxion Announces Business Update and Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/18/2023 03:57:08 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 08/18/2023 01:28:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/17/2023 08:58:50 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/17/2023 08:45:16 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/11/2023 08:45:16 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/04/2023 08:45:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/01/2023 11:00:06 AM
- Evaxion announces financing commitments totaling up to USD 20 million with Negma Group • GlobeNewswire Inc. • 08/01/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/31/2023 08:45:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/31/2023 11:00:07 AM
- Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus • GlobeNewswire Inc. • 07/31/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/11/2023 01:14:39 PM
- Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial • GlobeNewswire Inc. • 06/03/2023 09:00:00 PM
- Evaxion Announces Business Update and First Quarter 2023 Financial Results • GlobeNewswire Inc. • 05/31/2023 12:30:00 PM
- Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01 • GlobeNewswire Inc. • 05/25/2023 09:00:00 PM
Green Egg to launch $150 million bond offer for quicklime products production kiln plant Sep 22, 2023 12:11 PM
Nate's Food Co. Announces Reverse Merger and Change of Control with JP Energy Group to Drive Global Expansion • NHMD • Sep 22, 2023 9:00 AM
Trio Petroleum Corp Provides Update on Testing of the HV-1 Discovery Well • TPET • Sep 21, 2023 9:38 AM
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation • GNPX • Sep 20, 2023 8:45 AM
Caduceus Provides Update on Its Plans for The Second Half of The Fiscal Year • CSOC • Sep 20, 2023 8:26 AM
RESILIENT ENERGY INC. (RENI) PURSUING ACQUISITION TARGETS • RENI • Sep 19, 2023 10:30 AM